When compared to other experimental anticancer agents, LiPyDau stands out due to its robust efficacy, delivering curative outcomes in several aggressive tumor models, including the genetically engineered Brca1−/−;p53−/− breast cancer model (KBP1) as well as patient-derived xenografts of lung adenocarcinoma, which further underscores its translational potential. This evidence concerns the gene HIVEP3 and breast carcinoma.